ARCHIVES

New Creatinine Test Raises Questions About Accuracy Of Carboplatin Dosing

This article is from The Cancer Letter archive.

Vol. 36 No. 36 | October 8, 2010

Download PDF Visit The Full Archive

Related Articles

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

Niederhuber Leads AACI

November 2, 2001

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

September 25, 1998

RFA On Natural Inhibitors Role In Prevention Released

April 2, 1982